@article{736675647a1c4fe2b33c940c4b8b865b,
title = "Efficacy, outcomes, and cost-effectiveness of desensitization using ivig and rituximab",
keywords = "Acute antibody-mediated rejection, Acute cellYmediated rejection, Broadly HLA sensitized, Desensitization, Dialysis cost, Economic cost model, IVIG, Kidney transplant outcomes, Markov model, Rituximab, Humans, Middle Aged, Male, Kidney Transplantation/methods, Immunoglobulins, Intravenous/therapeutic use, Female, Antibodies, Monoclonal, Murine-Derived/therapeutic use, Histocompatibility Testing, Graft Survival, Treatment Outcome, Health Care Costs, Cost-Benefit Analysis, Desensitization, Immunologic/economics, Aged, Kidney Failure, Chronic/therapy, Antibodies/metabolism, Cohort Studies",
author = "Vo, {Ashley A.} and Jeffrey Petrozzino and Kai Yeung and Aditi Sinha and Joseph Kahwaji and Alice Peng and Rafael Villicana and John MacKowiak and Jordan, {Stanley C.}",
year = "2013",
month = mar,
day = "27",
doi = "10.1097/TP.0b013e3182802f88",
language = "English",
volume = "95",
pages = "852--858",
journal = "Transplantation",
issn = "0041-1337",
number = "6",
}